PDCD1 and neoplasm: As expected, we observed up-regulation of known inhibitory immune checkpoints and markers of progressive T cell exhaustion39 (PDCD1, TIGIT, CTLA-4), all of which have demonstrated anti-tumor activity when inhibited alone or in combination with PD-1 inhibitors in various cancer indications15,35,40.